• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DYRK1A 负调控 CDK5-SOX2 通路和胶质母细胞瘤干细胞的自我更新。

DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.

机构信息

Charles Perkins Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.

出版信息

Int J Mol Sci. 2021 Apr 13;22(8):4011. doi: 10.3390/ijms22084011.

DOI:10.3390/ijms22084011
PMID:33924599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8069695/
Abstract

Glioblastoma display vast cellular heterogeneity, with glioblastoma stem cells (GSCs) at the apex. The critical role of GSCs in tumour growth and resistance to therapy highlights the need to delineate mechanisms that control stemness and differentiation potential of GSC. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) regulates neural progenitor cell differentiation, but its role in cancer stem cell differentiation is largely unknown. Herein, we demonstrate that DYRK1A kinase is crucial for the differentiation commitment of glioblastoma stem cells. DYRK1A inhibition insulates the self-renewing population of GSCs from potent differentiation-inducing signals. Mechanistically, we show that DYRK1A promotes differentiation and limits stemness acquisition via deactivation of CDK5, an unconventional kinase recently described as an oncogene. DYRK1A-dependent inactivation of CDK5 results in decreased expression of the stemness gene SOX2 and promotes the commitment of GSC to differentiate. Our investigations of the novel DYRK1A-CDK5-SOX2 pathway provide further insights into the mechanisms underlying glioblastoma stem cell maintenance.

摘要

胶质母细胞瘤表现出广泛的细胞异质性,以胶质母细胞瘤干细胞 (GSCs) 为顶点。GSCs 在肿瘤生长和对治疗的抵抗中的关键作用突出表明需要阐明控制 GSC 的干性和分化潜能的机制。双特异性酪氨酸磷酸化调节激酶 1A (DYRK1A) 调节神经祖细胞分化,但它在癌症干细胞分化中的作用在很大程度上尚不清楚。本文中,我们证明 DYRK1A 激酶对于胶质母细胞瘤干细胞的分化决定至关重要。DYRK1A 抑制可将 GSCs 的自我更新群体与有效的诱导分化信号隔离开来。在机制上,我们表明 DYRK1A 通过去激活 CDK5 来促进分化并限制干性获得,CDK5 是一种最近被描述为癌基因的非典型激酶。依赖于 DYRK1A 的 CDK5 失活导致干性基因 SOX2 的表达降低,并促进 GSC 向分化方向分化。我们对新型 DYRK1A-CDK5-SOX2 途径的研究为胶质母细胞瘤干细胞维持的机制提供了进一步的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/fb99b4445d9d/ijms-22-04011-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/52b54eb846e6/ijms-22-04011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/9fff07b52d9e/ijms-22-04011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/abe6d1c5756d/ijms-22-04011-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/53b29d5be9ee/ijms-22-04011-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/fb99b4445d9d/ijms-22-04011-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/52b54eb846e6/ijms-22-04011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/9fff07b52d9e/ijms-22-04011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/abe6d1c5756d/ijms-22-04011-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/53b29d5be9ee/ijms-22-04011-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c345/8069695/fb99b4445d9d/ijms-22-04011-g005.jpg

相似文献

1
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.DYRK1A 负调控 CDK5-SOX2 通路和胶质母细胞瘤干细胞的自我更新。
Int J Mol Sci. 2021 Apr 13;22(8):4011. doi: 10.3390/ijms22084011.
2
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.抑制 DYRK1A 会使 EGFR 不稳定,并减少 EGFR 依赖的神经胶质瘤生长。
J Clin Invest. 2013 Jun;123(6):2475-87. doi: 10.1172/JCI63623. Epub 2013 May 1.
3
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.DYRK1A 对于维持癌症干细胞特性是必需的,有助于口腔/口咽鳞状细胞癌的致瘤潜能。
Exp Cell Res. 2021 Aug 1;405(1):112656. doi: 10.1016/j.yexcr.2021.112656. Epub 2021 May 23.
4
Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.细胞朊蛋白与伴侣蛋白组织蛋白Hsp70/90的结合调节胶质母细胞瘤干细胞样细胞的增殖。
Stem Cell Res Ther. 2017 Apr 17;8(1):76. doi: 10.1186/s13287-017-0518-1.
5
Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).Src 和 PLK1 的双重抑制通过 Notch1-SOX2 信号通路调节 EGFRvIII 阳性脑肿瘤干细胞(GSCs)中的干性并诱导细胞凋亡。
Exp Cell Res. 2020 Nov 1;396(1):112261. doi: 10.1016/j.yexcr.2020.112261. Epub 2020 Sep 5.
6
A Novel Role of BIRC3 in Stemness Reprogramming of Glioblastoma.BIRC3在胶质母细胞瘤干性重编程中的新作用
Int J Mol Sci. 2021 Dec 28;23(1):297. doi: 10.3390/ijms23010297.
7
ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation.内质网应激和未折叠蛋白反应激活在脑胶质瘤中的作用:通过 Sox2 调控鉴定调节 GBM 干细胞的非经典 PERK 机制。
Cell Death Dis. 2019 Sep 18;10(10):690. doi: 10.1038/s41419-019-1934-1.
8
TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3.TRIM8通过PIAS3-STAT3调节胶质母细胞瘤的干性。
Mol Oncol. 2017 Mar;11(3):280-294. doi: 10.1002/1878-0261.12034. Epub 2017 Feb 15.
9
Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.靶向 DYRK1A/B 激酶调节 p21-cyclin D1-p27 信号通路并在人胶质母细胞瘤模型中诱导抗肿瘤活性。
J Cell Mol Med. 2021 Nov;25(22):10650-10662. doi: 10.1111/jcmm.17002. Epub 2021 Oct 28.
10
Growth-Inhibitory Activity of Bone Morphogenetic Protein 4 in Human Glioblastoma Cell Lines Is Heterogeneous and Dependent on Reduced SOX2 Expression.骨形态发生蛋白 4 对人神经胶质瘤细胞系的生长抑制活性具有异质性,且依赖于 SOX2 表达的降低。
Mol Cancer Res. 2020 Jul;18(7):981-991. doi: 10.1158/1541-7786.MCR-19-0638. Epub 2020 Mar 31.

引用本文的文献

1
Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.蛋白激酶 DYRK1B 的表达水平升高可诱导 A549 肺癌细胞呈现间充质特征。
BMC Cancer. 2024 Oct 31;24(1):1341. doi: 10.1186/s12885-024-13057-0.
2
Design, synthesis, and structure-activity relationship studies of 6-benzo[]indeno[1,2-]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors.作为DYRK1A/CLK1/CLK4/组蛋白Haspin激酶抑制剂的6-苯并[]茚并[1,2-]噻吩-6-酮衍生物的设计、合成及构效关系研究
RSC Med Chem. 2024 Oct 17;16(1):179-99. doi: 10.1039/d4md00537f.
3
CDK5: an oncogene or an anti-oncogene: location location location.

本文引用的文献

1
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.全球磷酸化蛋白质组学研究揭示DYRK1A调节胶质母细胞瘤细胞中的CDK1活性。
Cell Death Discov. 2021 Apr 16;7(1):81. doi: 10.1038/s41420-021-00456-6.
2
The Role of CDK5 in Tumours and Tumour Microenvironments.细胞周期蛋白依赖性激酶5在肿瘤及肿瘤微环境中的作用
Cancers (Basel). 2020 Dec 31;13(1):101. doi: 10.3390/cancers13010101.
3
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.TP5,一种异常活跃的CDK5/p25肽抑制剂:一种针对胶质母细胞瘤的新型治疗方法。
CDK5:原癌基因还是抑癌基因:位置位置位置。
Mol Cancer. 2023 Nov 23;22(1):186. doi: 10.1186/s12943-023-01895-8.
4
Cancer stem cell fate determination: mito-nuclear communication.肿瘤干细胞命运决定:线粒体-核通讯。
Cell Commun Signal. 2023 Jun 27;21(1):159. doi: 10.1186/s12964-023-01160-x.
5
Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity.尿石素 A 通过抑制 DYRK1A 活性对阿尔茨海默病表现出神经保护作用。
J Food Drug Anal. 2023 Jun 15;31(2):358-370. doi: 10.38212/2224-6614.3462.
6
SOX2 suppresses osteoblast differentiation of MC3T3-E1 cells through activating the transcription of LGR4.SOX2通过激活LGR4的转录来抑制MC3T3-E1细胞的成骨细胞分化。
In Vitro Cell Dev Biol Anim. 2023 Jan;59(1):1-9. doi: 10.1007/s11626-022-00740-4. Epub 2022 Dec 22.
7
Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells.从胶质瘤干细胞角度看整合素在胶质瘤中的病理生理作用
Front Cell Dev Biol. 2022 Sep 16;10:962481. doi: 10.3389/fcell.2022.962481. eCollection 2022.
8
The role of Cdk5 in neurological disorders.细胞周期蛋白依赖性激酶5在神经疾病中的作用。
Front Cell Neurosci. 2022 Jul 28;16:951202. doi: 10.3389/fncel.2022.951202. eCollection 2022.
9
The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target.染色体 21 激酶 DYRK1A:在癌症生物学中的新作用及其作为治疗靶点的潜力。
Oncogene. 2022 Apr;41(14):2003-2011. doi: 10.1038/s41388-022-02245-6. Epub 2022 Feb 26.
10
Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.小分子抑制剂配体对阿尔茨海默病中过度磷酸化 tau 诱导的线粒体和突触毒性的保护作用。
Hum Mol Genet. 2021 Dec 27;31(2):244-261. doi: 10.1093/hmg/ddab244.
Cancers (Basel). 2020 Jul 17;12(7):1935. doi: 10.3390/cancers12071935.
4
The Glioma Stem Cell Model in the Era of Single-Cell Genomics.单细胞基因组学时代的神经胶质瘤干细胞模型。
Cancer Cell. 2020 May 11;37(5):630-636. doi: 10.1016/j.ccell.2020.04.001.
5
Glioblastoma Stem Cells: Driving Resilience through Chaos.胶质母细胞瘤干细胞:通过混沌驱动韧性。
Trends Cancer. 2020 Mar;6(3):223-235. doi: 10.1016/j.trecan.2020.01.009. Epub 2020 Feb 3.
6
CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity.CDK5 依赖性磷酸化和 TRIM59 的核转位促进了大组蛋白 H2A1 的泛素化和致瘤性。
Nat Commun. 2019 Sep 5;10(1):4013. doi: 10.1038/s41467-019-12001-2.
7
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer.胶质母细胞瘤干细胞:致命癌症中肿瘤等级的启示。
Genes Dev. 2019 Jun 1;33(11-12):591-609. doi: 10.1101/gad.324301.119.
8
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.全基因组 CRISPR-Cas9 筛选揭示胶质母细胞瘤干细胞对替莫唑胺敏感性的遗传脆弱性和机制。
Cell Rep. 2019 Apr 16;27(3):971-986.e9. doi: 10.1016/j.celrep.2019.03.047.
9
A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response.基于蛋白质组学的综合相互作用筛选将 DYRK1A 与 RNF169 以及 DNA 损伤反应联系起来。
Sci Rep. 2019 Apr 12;9(1):6014. doi: 10.1038/s41598-019-42445-x.
10
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.成神经管细胞瘤、经典型和间充质神经胶质瘤患者来源细胞系和异种移植模型参考集。
Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.